Jan. 21 at 5:21 PM
$LRMR their candidate for the BLA submission this year is Nomlabofusp, its used to treat a neurodegenerative disease called Friedreich’s ataxia.
There is only one drug in the market used to manage this disease which doesnt treat the root cause of the disease
$LRMR drug claims their drug can treat the root cause of it especially for children. early intervention is what they are targetting. estimated revenue is around
$800 million a year at a very conservative share, stock sticks is 1/3 of that right now, and this is not including the other stuff in the pipeline
If they get their BLA submission together for this year and get the accelerated approval we can see
$5 to
$6 soon
Nasdaq says 99% of the stock is own by institutions, its obviously not that, but means a lot of institution interest on this stock, a direct last year bought 9,000,000 shares last year at
$3.2.
